GSK upgrades guidance

GSK Plc has upgraded its financial guidance for 2023 following strong sales for its HIV products and general medicines division in the first six months of the year. Turnover was £13.9 billion for the first half, up by 13% from a year earlier and was £7.13 billion for the third quarter, up by 10%. These figures exclude sales of Covid-19 products developed for the pandemic which were down compared with the previous year. Strong demand was reported in the third quarter for the HIV medicines Cabenuva and Apretude, and for the respiratory drug Trelegy.